Hospital Acquired Infection Treatment Market (Infection Type - Urinary Tract Infections, Ventilator Associated Pneumonia, Bloodstream Infections, Surgical Site Infections, Gastrointestinal Infection, ENT Infections, Skin Infection, and Bone Infection; Treatment Type - Antibacterial, Antiviral, Antifungal Treatment, Antiparasitic, Antiprotozoal, and Anti-TB Treatment; Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Drug Store, and E-Commerce) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2019 - 2030

Description

Hospital Acquired Infection Treatment Market Rides on Increased Prevalence of HAI Worldwide

A hospital-acquired infection (HAI) is also otherwise known as a nosocomial infection. It is a type of infection that is contacted in a healthcare facility or in a hospital. The infection is also known as health care–associated infection in an effort to emphasize on both non-hospital and hospital settings. A rise in the incidences of such an infection is expected to give a boost to the global hospital acquired infection treatment market over the timeframe of projection.

Fungal, bacterial, and viral pathogens cause hospital-acquired infections. The most common types are surgical site infection (SSI), urinary tract infection (UTI), pneumonia (such as ventilator-associated pneumonia), and bloodstream infection (BSI).

Market Growth to be driven by Vulnerability of Newborn Babies toward HAI

In some cases, hospital acquired infection manifests itself weeks after discharge from the hospital though it had been contacted in the hospital. The infection could also infect the hospital staff and caregivers associated with taking care of such patients. Such high prevalence and contagiousness of the infection is likely to spell growth for the global hospital acquired infection treatment market in near future.

Many antimicrobial drugs have proven to be highly effective in treating a wide range of hospital-related infections that are highly prevalent across the globe. Treatments of hospital-acquired infections comprise the following

  • Antifungal therapy
  • Antiviral therapy

The most sterilized sections of the hospital are the neonatal intensive care units (NICUs), which keeps infants as they are more vulnerable to such infections during the span of their hospital stay.  The National Institute of Child Health and Human Development (NICHD) conducted a study titled “Neonatal Network”. The study projected that around 29% of the infants born at 25 to 28 weeks of gestation period and 46% of the newborns born at less than 25 weeks of gestation are estimated to experience severe hospital acquired infection over the period of hospitalization at NICU. High vulnerability of infants likely to play an important role in the development of the global hospital acquired infection treatment market in near future. 

The global hospital acquired infection treatment (HAI) market for the historical period 2017–2018 and forecast period 2019–2027, unhygienic conditions and improper sterilization treatment, lack of surveillance systems for HAIs, high susceptibility of neonatal population, and rising geriatric population are projected to drive the global hospital acquired infection treatment (HAI) market during the forecast period

According to the report, the global hospital acquired infection treatment (HAI) market was valued at US$ 31.0 Bn in 2018 and is anticipated to expand at a CAGR of 2.5% from 2019 to 2027

fa global hospital acquired infection treatment market

To know the scope of our report Get a Sample on Hospital Acquired Infection Treatment Market

Rising Geriatric Population and Unhygienic Conditions and Improper Sterilization Treatment: Key Drivers

Continuous increase in the geriatric population is expected to be one of the potential drivers of the hospital acquired infection (HAI) treatment market during the forecast period. The geriatric population is at high risk of infection due to the age-related immunity decline, known as immunosenescence. Moreover, such patients required more time to heal and hospital stay to get recovered.

Increase in need for effective antibacterial treatment options for the geriatric population is expected to drive the demand for the hospital acquired infection treatment (HAI) market

According to WHO estimates, the global geriatric population is likely to reach around 2 billion (22% of global population) by 2050, which is currently 566 million.

Hospital acquired infections are one the highly frequent adverse events in the health care industry. Presence of unhygienic conditions around and inside the hospital along with improper sterilization techniques applied in the hospitals are increasing the prevalence of hospital acquired infection in low income and middle income countries.

According to an article published by Global Antibiotic Resistance Partnership (GARP), more than 190,000 neonatal deaths occurred in India annually due to infection

Get a glimpse of the in-depth analysis through our Report Brochure

Lack of Surveillance Systems for HAIs Boost Market Growth

Increasing prevalence of HAIs is because most countries do not have surveillance systems for HAIs, while the countries that have the systems in place often face difficulties with the complexity and lack of standardized criteria for diagnosing the infections. Countries in North America and Europe have surveillance systems for HAI monitoring while countries in Asia Pacific and rest of the world do not have the systems, which makes it difficult to control the outbreak of endemics in these regions.

The Healthcare-Associated Infections Surveillance Network (HAI-Net), National Healthcare Safety Network (NHSN), and Japan Nosocomial Infection Surveillance System (JANIS) are some of the surveillance systems working efficiently in developed countries

Multi-drug Resistant Bacteria Making Presently Available Antibacterial Drugs Outdated to Hamper Market

Multi-drug resistance is one of the most common causes of failure in treatment for bacterial infection. Bacteria are the only species that can survive even after frequent exposure to one or more antibiotics and develop drug resistance.

Moreover, these infections result in higher rate of disability and death compared to the infections that are easily treatable with antibiotics. Multi-drug resistance is affecting the HAI treatment market due to the shift of treatment process.

Major types of multi-drug resistant bacteria are methicillin resistant Staphylococcus aureus (MRSA), vancomycin-resistant enterococcus (VRE), and multidrug-resistant Mycobacterium tuberculosis (MDR-TB).

 Global Hospital Acquired Infection Treatment (HAI) Market: Competitive Landscape

This report profiles major players in the global hospital acquired infection treatment (HAI) market based on various attributes such as company overview, financial overview, product portfolio, business strategies, and recent developments

The global hospital acquired infection treatment (HAI) market is highly fragmented, with the presence of a number of international as well as regional players

Leading players operating in the global hospital acquired infection treatment (HAI) market

  • Abbott Laboratories
  • Pfizer, Inc.
  • Bayer AG
  • AstraZeneca
  • F. Hoffmann-La Roche Ltd.
  • Johnson & Johnson Services, Inc.
  • Merck & Co., Inc.
  • Cipla Inc.
  • GlaxoSmithKline plc
  • Aridis Pharmaceuticals, Inc
  • Astellas Pharma Inc.
  • Daiichi Sankyo, Inc.
  • Bristol-Myers Squibb Company
  • Eli Lilly and Company among others.

Key Questions Answered in Global Hospital acquired infection treatment (HAI) Market Report

  • What is the scope of growth of product companies in the global hospital acquired infection treatment (HAI) market?
  • What will be the Y-o-Y growth of the global hospital acquired infection treatment (HAI) market between 2019 and 2027?
  • What is the influence of changing trends in technologies on the global hospital acquired infection treatment (HAI) market?
  • Will North America continue to be the most profitable market for hospital acquired infection treatment (HAI) providers?
  • Which factors are anticipated to hamper the growth of the global hospital acquired infection treatment (HAI) market during the forecast period?
  • Which are the leading companies in the global hospital acquired infection treatment (HAI) market?

Global Hospital acquired infection treatment (HAI) Market - Segmentation

Infection Type

  • Urinary Tract Infection
  • Ventilator-Associated Pneumonia
  • Bloodstream Infection
  • Surgical Site Infection
  • Other (Gastrointestinal Infection, ENT Infections, Skin Infection and Bone Infection)

Treatment

  • Antibacterial Treatment
  • Beta-Lactams
  • Quinolones
  • Vancomycin
  • Other
  • Antiviral Treatment
  • Acyclovir
  • Foscarnet
  • Antifungal Treatment
  • Amphotericin B
  • Triazoles
  • Other (Antiparasitic, Antiprotozoal and Anti TB Treatment)

Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Drug Store
  • E-Commerce
  • Other

Region

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East & Africa

TABLE OF CONTENT

1.  Preface

     1.1.  Market Definition and Scope

     1.2.  Market Segmentation

     1.3.  Key Research Objectives

     1.4.  Research Highlights

 2.  Assumptions and Research Methodology

 3.  Executive Summary : Global Hospital Acquired Infection Treatment (HAI) Market

 4.  Market Overview

     4.1.  Introduction

     4.2.  Overview

     4.3.  Market Dynamics

         4.3.1. Drivers

         4.3.2. Restraints

         4.3.3. Opportunities

     4.4. Global Hospital Acquired Infection Treatment (HAI) Market Analysis and Forecasts, 2017–2030

     4.5. Porter’s Five Force Analysis

 5.  Key Insights

     5.1. Guidelines for Hospital Acquired Infection Treatment

     5.2. Epidemiology of Hospital Acquired Infection, By Key Countries

     5.3. Regulations for Controlling Hospital Acquired Infection, By Region

     5.4. Future Market Outlook

 6.  Global Hospital Acquired Infection Treatment (HAI) Market Analysis and Forecasts, By Infection Type 

     6.1. Introduction & Definition

     6.2. Key Findings / Developments

     6.3. Market Value  Forecast By Infection Type, 2017–2030

         6.3.1. Urinary Tract Infection 

         6.3.2. Ventilator-Associated Pneumonia 

         6.3.3. Bloodstream Infection  

         6.3.4. Surgical Site Infection

         6.3.5. Other (Gastrointestinal Infection, ENT Infections, Skin Infection and Bone Infection)

     6.4. Market Attractiveness By Infection Type 

 7.  Global Hospital Acquired Infection Treatment (HAI) Market Analysis and Forecasts, By Treatment 

     7.1. Introduction & Definition

     7.2. Key Findings / Developments

     7.3. Market Value  Forecast By Treatment, 2017–2030

         7.3.1. Antibacterial Treatment

             7.3.1.1. Beta-Lactams

             7.3.1.2. Quinolones

             7.3.1.3. Vancomycin

             7.3.1.4. Other

         7.3.2. Antiviral Treatment 

             7.3.2.1. Acyclovir 

             7.3.2.2. Foscarnet 

         7.3.3. Antifungal Treatment 

             7.3.3.1. Amphotericin B 

             7.3.3.2. Triazoles

         7.3.4. Other (Antiparasitic, Antiprotozoal and Anti TB Treatment)

     7.4. Market Attractiveness By Treatment 

 8.  Global Hospital Acquired Infection Treatment (HAI) Market Analysis and Forecasts, By Distribution Channel 

     8.1. Introduction & Definition

     8.2. Key Findings / Developments

     8.3. Market Value  Forecast By Distribution Channel, 2017–2030

         8.3.1. Hospital Pharmacies 

         8.3.2. Retail Pharmacies

         8.3.3. Drug Store 

         8.3.4. E-Commerce 

         8.3.5. Other

     8.4. Market Attractiveness By Distribution Channel 

 9.  Global Hospital Acquired Infection Treatment (HAI) Market Analysis and Forecasts, By Region

     9.1. Key Findings

     9.2. Market Value  Forecast By Region

         9.2.1. North America 

         9.2.2. Europe 

         9.2.3. Asia Pacific 

         9.2.4. Latin America 

         9.2.5. Middle East & Africa 

     9.3. Market Attractiveness By Region

 10. North America Hospital Acquired Infection Treatment (HAI) Market Analysis and Forecast

     10.1. Introduction

     10.2. Market Value  Forecast By Infection Type, 2017–2030

         10.2.1. Urinary Tract Infection 

         10.2.2. Ventilator-Associated Pneumonia 

         10.2.3. Bloodstream Infection  

         10.2.4. Surgical Site Infection

         10.2.5. Other (Gastrointestinal Infection, ENT Infections, Skin Infection and Bone Infection)

     10.3. Market Value  Forecast By Treatment, 2017–2030

         10.3.1. Antibacterial Treatment

             10.3.1.1. Beta-Lactams

             10.3.1.2. Quinolones

             10.3.1.3. Vancomycin

             10.3.1.4. Other

         10.3.2. Antiviral Treatment 

             10.3.2.1. Acyclovir 

             10.3.2.2. Foscarnet 

         10.3.3. Antifungal Treatment 

             10.3.3.1. Amphotericin B 

             10.3.3.2. Triazoles

         10.3.4. Other (Antiparasitic, Antiprotozoal and Anti TB Treatment)

     10.4. Market Value  Forecast By Distribution Channel, 2017–2030

         10.4.1. Hospital Pharmacies 

         10.4.2. Retail Pharmacies

         10.4.3. Drug Store 

         10.4.4. E-Commerce 

         10.4.5. Other

     10.5. Market Value  Forecast By Country, 2017–2030

         10.5.1. U.S.

         10.5.2. Canada

     10.6. Market Attractiveness Analysis 

         10.6.1. By Infection Type 

         10.6.2. By Treatment 

         10.6.3. By Distribution Channel 

         10.6.4. By Country

 11. Europe Hospital Acquired Infection Treatment (HAI) Market Analysis and Forecast

     11.1. Introduction

     11.2. Market Value  Forecast By Infection Type, 2017–2030

         11.2.1. Urinary Tract Infection 

         11.2.2. Ventilator-Associated Pneumonia 

         11.2.3. Bloodstream Infection  

         11.2.4. Surgical Site Infection

         11.2.5. Other (Gastrointestinal Infection, ENT Infections, Skin Infection and Bone Infection)

     11.3. Market Value  Forecast By Treatment, 2017–2030

         11.3.1. Antibacterial Treatment

             11.3.1.1. Beta-Lactams

             11.3.1.2. Quinolones

             11.3.1.3. Vancomycin

             11.3.1.4. Other

         11.3.2. Antiviral Treatment 

             11.3.2.1. Acyclovir 

             11.3.2.2. Foscarnet 

         11.3.3. Antifungal Treatment 

             11.3.3.1. Amphotericin B 

             11.3.3.2. Triazoles

         11.3.4. Other (Antiparasitic, Antiprotozoal and Anti TB Treatment)

     11.4. Market Value  Forecast By Distribution Channel, 2017–2030

         11.4.1. Hospital Pharmacies 

         11.4.2. Retail Pharmacies

         11.4.3. Drug Store 

         11.4.4. E-Commerce 

         11.4.5. Other

     11.5. Market Value  Forecast By Country, 2017–2030

         11.5.1. Germany

         11.5.2. U.K.

         11.5.3. France

         11.5.4. Spain

         11.5.5. Italy

         11.5.6. Rest of Europe

     11.6. Market Attractiveness Analysis 

         11.6.1. By Infection Type 

         11.6.2. By Treatment 

         11.6.3. By Distribution Channel 

         11.6.4. By Country

 12. Asia Pacific Hospital Acquired Infection Treatment (HAI) Market Analysis and Forecast

     12.1. Introduction

     12.2. Market Value  Forecast By Infection Type, 2017–2030

         12.2.1. Urinary Tract Infection 

         12.2.2. Ventilator-Associated Pneumonia 

         12.2.3. Bloodstream Infection  

         12.2.4. Surgical Site Infection

         12.2.5. Other (Gastrointestinal Infection, ENT Infections, Skin Infection and Bone Infection)

     12.3. Market Value  Forecast By Treatment, 2017–2030

         12.3.1. Antibacterial Treatment

             12.3.1.1. Beta-Lactams

             12.3.1.2. Quinolones

             12.3.1.3. Vancomycin

             12.3.1.4. Other

         12.3.2. Antiviral Treatment 

             12.3.2.1. Acyclovir 

             12.3.2.2. Foscarnet 

         12.3.3. Antifungal Treatment 

             12.3.3.1. Amphotericin B 

             12.3.3.2. Triazoles

         12.3.4. Other (Antiparasitic, Antiprotozoal and Anti TB Treatment)

     12.4. Market Value  Forecast By Distribution Channel, 2017–2030

         12.4.1. Hospital Pharmacies 

         12.4.2. Retail Pharmacies

         12.4.3. Drug Store 

         12.4.4. E-Commerce 

         12.4.5. Other

     12.5. Market Value  Forecast By Country, 2017–2030

         12.5.1. China

         12.5.2. Japan

         12.5.3. India

         12.5.4. Australia & New Zealand

         12.5.5. Rest of Asia Pacific

     12.6. Market Attractiveness Analysis 

         12.6.1. By Infection Type 

         12.6.2. By Treatment 

         12.6.3. By Distribution Channel 

         12.6.4. By Country

 13. Latin America Hospital Acquired Infection Treatment (HAI) Market Analysis and Forecast

     13.1. Introduction

     13.2. Market Value  Forecast By Infection Type, 2017–2030

         13.2.1. Urinary Tract Infection 

         13.2.2. Ventilator-Associated Pneumonia 

         13.2.3. Bloodstream Infection  

         13.2.4. Surgical Site Infection

         13.2.5. Other (Gastrointestinal Infection, ENT Infections, Skin Infection and Bone Infection)

     13.3. Market Value  Forecast By Treatment, 2017–2030

         13.3.1. Antibacterial Treatment

             13.3.1.1. Beta-Lactams

             13.3.1.2. Quinolones

             13.3.1.3. Vancomycin

             13.3.1.4. Other

         13.3.2. Antiviral Treatment 

             13.3.2.1. Acyclovir 

             13.3.2.2. Foscarnet 

         13.3.3. Antifungal Treatment 

             13.3.3.1. Amphotericin B 

             13.3.3.2. Triazoles

         13.3.4. Other (Antiparasitic, Antiprotozoal and Anti TB Treatment)

     13.4. Market Value  Forecast By Distribution Channel, 2017–2030

         13.4.1. Hospital Pharmacies 

         13.4.2. Retail Pharmacies

         13.4.3. Drug Store 

         13.4.4. E-Commerce 

         13.4.5. Other

     13.5. Market Value  Forecast By Country, 2017–2030

         13.5.1. Brazil

         13.5.2. Mexico

         13.5.3. Rest of Latin America

     13.6. Market Attractiveness Analysis 

         13.6.1. By Infection Type 

         13.6.2. By Treatment 

         13.6.3. By Distribution Channel 

         13.6.4. By Country

 14. Middle East & Africa Hospital Acquired Infection Treatment (HAI) Market Analysis and Forecast

     14.1. Introduction

     14.2. Market Value  Forecast By Infection Type, 2017–2030

         14.2.1. Urinary Tract Infection 

         14.2.2. Ventilator-Associated Pneumonia 

         14.2.3. Bloodstream Infection  

         14.2.4. Surgical Site Infection

         14.2.5. Other (Gastrointestinal Infection, ENT Infections, Skin Infection and Bone Infection)

     14.3. Market Value  Forecast By Treatment, 2017–2030

         14.3.1. Antibacterial Treatment

             14.3.1.1. Beta-Lactams

             14.3.1.2. Quinolones

             14.3.1.3. Vancomycin

             14.3.1.4. Other

         14.3.2. Antiviral Treatment 

             14.3.2.1. Acyclovir 

             14.3.2.2. Foscarnet 

         14.3.3. Antifungal Treatment 

             14.3.3.1. Amphotericin B 

             14.3.3.2. Triazoles

         14.3.4. Other (Antiparasitic, Antiprotozoal and Anti TB Treatment)

     14.4. Market Value  Forecast By Distribution Channel, 2017–2030

         14.4.1. Hospital Pharmacies 

         14.4.2. Retail Pharmacies

         14.4.3. Drug Store 

         14.4.4. E-Commerce 

         14.4.5. Other

     14.5. Market Value  Forecast By Country, 2017–2030

         14.5.1. GCC Countries

         14.5.2. South Africa

         14.5.3. Rest of Middle East & Africa

     14.6. Market Attractiveness Analysis 

         14.6.1. By Infection Type 

         14.6.2. By Treatment 

         14.6.3. By Distribution Channel 

         14.6.4. By Country

 15. Competition Landscape

     15.1. Market Player – Competition Matrix (By Tier and Size of companies)

     15.2. Market Share Analysis By Company (2018)

     15.3. Company Profiles

         15.3.1. Abbott Laboratories

             15.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)

             15.3.1.2. Company Financials

             15.3.1.3. Growth Strategies

             15.3.1.4. SWOT Analysis

         15.3.2. Pfizer Inc. 

             15.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)

             15.3.2.2. Company Financials

             15.3.2.3. Growth Strategies

             15.3.2.4. SWOT Analysis

         15.3.3. Bayer AG

             15.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)

             15.3.3.2. Company Financials

             15.3.3.3. Growth Strategies

             15.3.3.4. SWOT Analysis

         15.3.4. Cepheid, Inc.

             15.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)

             15.3.4.2. Company Financials

             15.3.4.3. Growth Strategies

             15.3.4.4. SWOT Analysis

         15.3.5. AstraZeneca plc

             15.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)

             15.3.5.2. Company Financials

             15.3.5.3. Growth Strategies

             15.3.5.4. SWOT Analysis

         15.3.6. F. Hoffmann-La Roche Ltd

             15.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)

             15.3.6.2. Company Financials

             15.3.6.3. Growth Strategies

             15.3.6.4. SWOT Analysis

         15.3.7. Johnson & Johnson Services, Inc.

             15.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)

             15.3.7.2. Company Financials

             15.3.7.3. Growth Strategies

             15.3.7.4. SWOT Analysis

         15.3.8. Merck & Co., Inc. 

             15.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)

             15.3.8.2. Company Financials

             15.3.8.3. Growth Strategies

             15.3.8.4. SWOT Analysis

         15.3.9. Cipla Inc.

             15.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)

             15.3.9.2. Company Financials

             15.3.9.3. Growth Strategies

             15.3.9.4. SWOT Analysis

         15.3.10. GlaxoSmithKline plc. 

             15.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)

             15.3.10.2. Company Financials

             15.3.10.3. Growth Strategies

             15.3.10.4. SWOT Analysis

         15.3.11. Aridis Pharmaceuticals, Inc.

             15.3.11.1. Company Overview (HQ, Business Segments, Employee Strength)

             15.3.11.2. Company Financials

             15.3.11.3. Growth Strategies

             15.3.11.4. SWOT Analysis

         15.3.12. Astellas Pharma Inc.

             15.3.12.1. Company Overview (HQ, Business Segments, Employee Strength)

             15.3.12.2. Company Financials

             15.3.12.3. Growth Strategies

             15.3.12.4. SWOT Analysis

         15.3.13. Daiichi Sankyo, Inc.

             15.3.13.1. Company Overview (HQ, Business Segments, Employee Strength)

             15.3.13.2. Company Financials

             15.3.13.3. Growth Strategies

             15.3.13.4. SWOT Analysis

         15.3.14. Bristol-Myers Squibb Company

             15.3.14.1. Company Overview (HQ, Business Segments, Employee Strength)

             15.3.14.2. Company Financials

             15.3.14.3. Growth Strategies

             15.3.14.4. SWOT Analysis

         15.3.15. Eli Lilly and Company

             15.3.15.1. Company Overview (HQ, Business Segments, Employee Strength)

             15.3.15.2. Company Financials

             15.3.15.3. Growth Strategies

             15.3.15.4. SWOT Analysis

Choose License Type

Checkout Inquiry Sample